News | June 07, 2021
Bayer acquires Noria and PSMA Therapeutics
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
Integration of various regulatory agencies with a single-window system and putting in place a transparent, stable, predictable and easy to navigate interface.
The price increases are due to the rising costs of raw materials.
Subscribe To Our Newsletter & Stay Updated
